DOI QR코드

DOI QR Code

Efficacy and Safety of Docetaxel or Epirubicin, Combined with Cisplatin and Fluorouracil, (DCF and ECF) Regimens as First Line Chemotherapy for Advanced Gastric Cancer: a Retrospective Analysis from Turkey

  • Teker, Fatih (Department of Medical Oncology, Medical School, 19 Mayis University) ;
  • Yilmaz, Bahiddin (Department of Medical Oncology, Medical School, 19 Mayis University) ;
  • Kemal, Yasemin (Department of Medical Oncology, Medical School, 19 Mayis University) ;
  • Kut, Engin (Department of Medical Oncology, Medical School, 19 Mayis University) ;
  • Yucel, Idris (Department of Medical Oncology, Medical School, 19 Mayis University)
  • Published : 2014.08.30

Abstract

Objectives: Advanced gastric cancer (AGC) patients have a poor prognosis. The best benefit of chemotherapy is usually achieved by first line setting. Very few studies have compared combination regimens. This study was designed to compare two combination regimens. Methods: Patients with advanced gastric cancer receiving first line chemotherapy were retrospectively collected, and divided into two groups, receiving DCF (docetaxel, cisplatin and fluorouracil) or ECF (epirubicin, cisplatin and fluorouracil) regimens. Data were collected for the retrospective analysis in a single center. Results: Eighty-six patients were eligible for analysis. Median overall survival (OS) was 10.0 months in the ECF group and 11.0 months in the DCF group (p=0.31). Median progression free survival (PFS) for ECF and DCF was equal at 6.0 months. Second line chemotherapy were administered in more than one third of patients. Both regimens had similar toxicity. Conclusions: This is the first study investigating the outcomes of gastric cancer chemotherapy in this region. ECF and DCF regimens have similar efficacy and a similar tolerability profile for first line treatment of advanced gastric cancer. The decision of the first line chemotherapy in advanced gastric cancer could be improved with patient selection according to clinical parameters and molecular markers.

Keywords

Gastric cancer;chemotherapy;TCF protocol;ECF regimen

References

  1. Ajani JA, Moiseyenko VM, Tjulandin S, et al (2007). Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group. J Clin Oncol, 25, 3210-16. https://doi.org/10.1200/JCO.2006.08.3956
  2. Bang YJ, Van Cutsem E, Feyereislova A et al (2010). Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet, 28, 687-97.
  3. Cao X-Y, Jia Z-F, Cao D-H, et al (2013). DNMT3a rs1550117 Polymorphism association with increased risk of Helicobacter pylori infection. Asian Pac J Cancer Prev, 14, 5713-18. https://doi.org/10.7314/APJCP.2013.14.10.5713
  4. Chen X-L, Chen X-Z, Yang C, et al (2013). Docetaxel, cisplatin and fluorouracil (DCF) regimen compared with non-taxanecontaining palliative chemotherapy for gastric carcinoma: a systematic review and meta-analysis. PLoS ONE, 8, 603320
  5. Di Lauro L1, Vici P, Belli F et al (2013). Docetaxel, oxaliplatin, and capecitabine combination chemotherapy for metastatic gastric cancer. Gastric Cancer. Dec 8. [Epub ahead of print].
  6. Gao J, He Q, Hua D et al (2013). Polymorphism of TS 3'-UTR predicts survival of Chinese advanced gastric cancer patients receiving first-line capecitabine plus paclitaxel. Clin Transl Oncol, 15, 619-25. https://doi.org/10.1007/s12094-012-0979-8
  7. Gao H, Ding X, Wei D et al (2010). Docetaxel versus epirubic in combined with cisplatin, leucovorin and fluorouracil for advanced gastric carcinoma as first line therapy: a randomized clinical trial. Chin J Clin Oncol, 15, 529-533.
  8. Kucukzeybek Y, Dirican A, Erten C, et al (2012). Second-line irinotecan after cisplatin, fluoropyrimidin and docetaxel for chemotherapy of metastatic gastric cancer. Asian Pac J Cancer Prev, 13, 2771-4. https://doi.org/10.7314/APJCP.2012.13.6.2771
  9. Luigi Di Lauro, Patrizia Vici, Franca Belli et al (2013). Docetaxel, oxaliplatin, and capecitabine combination chemotherapy for metastatic gastric cancer. Gastric Cancer, Dec 8, [Epub ahead of print].
  10. Matsuda T, Saika K (2013). The 5-year relative survival rate of stomach cancer in the USA, Europe and Japan. Jpn J Clin, 43, 1157-58 https://doi.org/10.1093/jjco/hyt166
  11. Nagini S (2012). Carcinoma of the stomach: a review of epidemiology, pathogenesis, molecular genetics and chemoprevention. World J Gastrointest Oncol, 4, 156-69. https://doi.org/10.4251/wjgo.v4.i7.156
  12. Nomura A. Stomach cancer, in Schottenfeld D (1996). Cancer epidemiology and prevention 2nd ed. Oxford University Press, pp. 707-24.
  13. Ozaydin N, Turkyilmaz SA, Cali S (2013). Prevalence and risk factors of helicobacter pylori in Turkey: a nationallyrepresentative, cross-sectional, screening with the $^{13}C$-Urea breath test. BMC Public Health, 13, 1215. https://doi.org/10.1186/1471-2458-13-1215
  14. Paunder RE (1995). The prevention of H. pylori in different countries. Aliment Pharmacol Ther, 9, 33-40.
  15. Parkin DM (2002). Global cancer statistics. CA Cancer J Clin, 55, 74-108.
  16. Roth AD1, Fazio N, Stupp R et al (2007). Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss group for clinical cancer research. J Clin Oncol, 25, 3217-23. https://doi.org/10.1200/JCO.2006.08.0135
  17. Selcukbiricik F, Tural D, Bilici A et al (2013). Clinicopathological features and localization of gastric cancers and their effects on survival in Turkey. Asian Pac J Cancer Prev, 14, 553-6. https://doi.org/10.7314/APJCP.2013.14.1.553
  18. Tozawa K, Oshima T, Kobayashi T et al (2008). Oxaliplatin in treatment of the cisplatin resistant MKN45 cell line of gastric cancer. Anticancer Res, 28, 2087-92.
  19. Van Cutsem E, MoiseyenkoVM, Tjulandin S, et al (2006). Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol, 24, 4991-7. https://doi.org/10.1200/JCO.2006.06.8429
  20. Wagner AD, Unverzagt S, Grothe W, et al (2010). Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev, [Epub ahead of print].
  21. Wagner AD, Grothe W, Haerting et al (2006). Chemoth advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol, 24, 2903-9. https://doi.org/10.1200/JCO.2005.05.0245
  22. Yeh YS1, Tsai HL, Ma CJ et al (2012). A retrospective study of the safety and efficacy of a first-line treatment with modified FOLFOX-4 in unresectable advanced or recurrent gastric cancer patients. Chemotherapy, 58, 411-8. https://doi.org/10.1159/000345742
  23. Zhang XP1, Bai ZB, Chen BA et al (2012). Polymorphisms of dihydropyrimidine dehydrogenase gene and clinical outcomes of gastric cancerpatients treated with fluorouracilbased adjuvant chemotherapy in Chinese population. Chin Med J, 125, 741-6.

Cited by

  1. Efficacy and safety of taxane-based systemic chemotherapy of advanced gastric cancer: A systematic review and meta-analysis vol.7, pp.1, 2017, https://doi.org/10.1038/s41598-017-05464-0
  2. A Retrospective Comparison of Trastuzumab Plus Cisplatin and Trastuzumab Plus Capecitabine in Elderly HER2-Positive Advanced Gastric Cancer Patients vol.94, pp.34, 2015, https://doi.org/10.1097/MD.0000000000001428